Evaluation of p-glycoprotein alterations in treatment-resistant depression: a [18F]MC225 PET study

Prior treatment

• Use of medications with a known effect to P-gp activity
• Presence of drug and alcohol abuse/dependence during the last 6 years

Other illness

• Additional psychiatric disorders
• Neurological or major medical illnesses
• Dementia or mild cognitive impairment

Age

• Age <18 years and > 65 years old

Other

• Absence of adequate visual and auditory acquity to perform imaging procedures
• Claustrophobia and/or inability to tolerate brain PET acquisition that would have an impact on the collection of a good quality scan
• Poor peripheral arterial and/or venus access that would interfere with radiopharmaceutical administration and/or blood sampling
• Traumatic brain injury with loss of consciousness
• Any brain abnormality or microvascular lesions
• Pregnancy, breastfeeding, or intention to undergo pregnancy within 6 months from the PET/CT scan
• Inability to provide written informed consent

• Age between 18 and 65 years old
• MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorder, 5th edition (DSM-5)
• At least 5 years of education
• Capability of completing imaging procedures
• Presence of a current TRD will be additionally required for TRD subjects, according to the most-commonly described criteria used by studies/guidelines for TRD, namely: nonresponse to a minimum of two prior antidepressant treatment attempts of an adequate dose and duration. Non-response will be defined as failure of an antidepressant treatment to induce symptoms remission, according to the NH-mental health study STAR D and experts definition. Treatment resistance/response in the last/current episode should not involve antidepressant which have been proven not to be substrates of P-gp
• Capability of providing written informed consent